Alone, Niraparib increases PD-L1 expression in ovarian cancer cells and enhances CD8+ T cell recruitment, activating an immune response via cGAS-STING, but is limited by immunosuppressive feedback from PD-L1. This evidence concerns the gene CGAS and ovarian carcinoma.